HCW Biologics Inc.
About HCW Biologics Inc.
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2020
- $4.1M
- Net income
- -$8.0M
- Total assets
- $24.5M
- Market cap
- $11.7M
- Gross margin
- 20.0%
- Operating margin
- -24270.7%
- Net margin
- -14677.1%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $54.2K
- Cost of revenue
- $43.4K
- Gross profit
- $10.8K
- Operating expenses
- $13.2M
- Operating income
- -$13.2M
- Income tax
- $0
- Net income
- -$8.0M
- EPS (basic)
- $-10.63
- EPS (diluted)
- $-10.63
Balance sheet
- Total assets
- $24.5M
- Current assets
- $2.3M
- Total liabilities
- $21.8M
- Current liabilities
- $21.1M
- Shareholders’ equity
- $2.8M
Cash flow
- Operating cash flow
- -$13.4M
- Investing cash flow
- $2.7M
- Financing cash flow
- $10.7M
- Net cash flow
- $0
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $11.7M
- EPS (diluted)
- $-10.63
- Shares outstanding
- 8.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 20, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $8.0M in FY2020.
- Gross margin of 20.0%, net margin -14677.1%.
- Trading 86% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review HCW Biologics Inc..
Write a review
News about HCW Biologics Inc.
News & sentiment via Polygon.io
